Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.
about
Genetic background in nonalcoholic fatty liver disease: A comprehensive reviewInterferon-λ: Immune Functions at Barrier Surfaces and BeyondA prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infectionZinc is a potent and specific inhibitor of IFN-λ3 signalling.Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis CIFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System.The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV CoinfectionInterferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types.The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease InhibitorsDuplex High-Resolution Melting Assay for the Simultaneous Genotyping of IL28B rs12979860 and PNPLA3 rs738409 Polymorphisms in Chronic Hepatitis C PatientsDonor IFNL4 Genotype Is Associated with Early Post-Transplant Fibrosis in Recipients with Hepatitis C.Expression of Interferon Lambda 4 Is Associated with Reduced Proliferation and Increased Cell Death in Human Hepatic Cells.Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma RiskAwareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.Cytokine levels contribute to the pathogenesis of minimal hepatic encephalopathy in patients with hepatocellular carcinoma via STAT3 activation.Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma.DNA methylation profiling identifies novel markers of progression in hepatitis B-related chronic liver disease.Association of Hepatitis C Virus Infection With CD4/CD8 Ratio in HIV-Positive Women.Responder Interferon λ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus CoinfectionInsights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease.Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review.MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.Type III Interferons in Hepatitis C Virus Infection.Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort.New perspectives of biomarkers for the management of chronic hepatitis B.Interferon Lambda: Modulating Immunity in Infectious Diseases.Involvement of NK Cells in IL-28B-Mediated Immunity against Influenza Virus Infection.Genetic and epigenetic mechanisms of NASH.Targeting IFN-λ: therapeutic implications.Gene-disease association with human IFNL locus polymorphisms extends beyond hepatitis C virus infections.A systematic review and meta-analysis of HCV clearance.The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B.Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C.IFNL4 rs368234815 TT>δG Variant is Associated with Liver Damage in Patients with Non-alcoholic Fatty Liver Disease.Relationship of Genotype for HLA B*57 and IFNL4 with Disease Progression in Female HIV Controllers.IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis.Serum microRNAs as predictors for liver fibrosis staging in hepatitis C virus-associated chronic liver disease patients.Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study.Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.
P2860
Q26780248-816CD4F3-E096-4DD2-9EFD-ECE277F96781Q26801049-DEC422CB-C049-4CE6-BA9A-D1C836924442Q33632714-E0FFB5BB-59F4-400B-8499-FA7CC75AADB3Q33720876-3633136F-BDB1-42BF-864C-A382E135E1BCQ33898567-8E0B1662-307E-42BB-AFF8-98801A2AFA44Q34504772-2F92107E-8016-4F22-914D-75AFC2D50C8CQ35849638-1365A835-6A3C-47A1-A9FB-F9BB2C72DC20Q36134478-094FD075-C15A-4DFB-948A-0921CF034625Q36155389-70B6A310-F0E7-4A80-8335-34199EE0A266Q36184217-93BB0B7A-6592-497C-AF5D-FC0FAF6A5344Q36201137-FAD134CB-0B38-418F-9324-B2FD70053109Q36274463-E2618B18-7B81-4313-8A8C-2118E92F570AQ36316508-446220B7-4A19-474A-A73F-72FF0F21D5A3Q36406176-55E9C212-B203-4A7B-962F-549502A6CC4CQ36499677-3BCCCC12-84F4-4F62-A0F8-BFCC9E5AC2DDQ36511162-251598D2-8E5F-4038-8A5C-B8B09EA12F99Q36871793-571E02DD-7F4A-444C-A3B0-A39D33DF07D3Q36921188-F0F2EE4D-DF11-470C-A47E-F12DEF2BAA06Q37003049-1D8E3904-330C-4B56-940C-DA82D7E63B2AQ37087800-5D503768-5084-4C16-B59E-301D82BE69C1Q37146192-5A08D628-06FB-49E8-AD53-DF1CE39BFF6BQ37264708-D94B73C1-F2A3-43C6-B34A-414881C0D828Q37528605-D52D7B6B-B3E5-4836-9474-4A8BD4BED0A3Q37546867-49203D56-A04D-47B4-A616-5671171E83EDQ37606546-23DD0D96-5005-4A2D-930C-6065C0CE4209Q37670446-962BC7E3-21D8-4BA8-9194-C9BDC6177328Q38668279-C633DFDB-6213-45CA-92D9-86A4003AE413Q38673496-99328A35-40E6-4D43-A425-7F9C7B09B572Q38816811-143F8A76-59AC-44B0-A6B0-BBAD14F2A62FQ38859455-ABC8BBBF-CC5B-499E-840B-E2D10B37FCD9Q38928083-8589E28F-5CEF-4713-AE16-D2CA5AB489A5Q39008629-9527D363-26B6-4EDB-9E64-04341EA88AD2Q40098532-42940C82-5CB6-4BA0-86C7-1E4A2D81C18DQ40121061-09253DA6-3254-4A4E-8044-FEB70F926355Q40186760-B0A7C2B6-E621-463D-913F-C44BB1950CB4Q40258100-C3959EAD-74AE-47C6-A9AA-E112155CD7AFQ40330653-DB642962-7201-4EC9-8F17-8EACF61A5F02Q40390455-3E321880-1CD0-45D5-8F25-782D9F13030FQ40483611-475A4CEF-A6E7-43C2-8E1E-A7F651B5197CQ40813737-E4B60B95-8117-42A6-9B0C-17060DEB6232
P2860
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Interferon-λ rs12979860 genoty ...... n-viral chronic liver disease.
@ast
Interferon-λ rs12979860 genoty ...... n-viral chronic liver disease.
@en
type
label
Interferon-λ rs12979860 genoty ...... n-viral chronic liver disease.
@ast
Interferon-λ rs12979860 genoty ...... n-viral chronic liver disease.
@en
prefLabel
Interferon-λ rs12979860 genoty ...... n-viral chronic liver disease.
@ast
Interferon-λ rs12979860 genoty ...... n-viral chronic liver disease.
@en
P2093
P2860
P50
P356
P1476
Interferon-λ rs12979860 genoty ...... on-viral chronic liver disease
@en
P2093
Ahmed M Hashem
Alessandra Mangia
Christopher Liddle
David R Booth
Duncan McLeod
Elisabetta Bugianesi
Gregory J Dore
Henry L K Chan
International Hepatitis C Genetics Consortium (IHCGC)
Jacob George
P2860
P2888
P356
10.1038/NCOMMS7422
P407
P50
P577
2015-03-05T00:00:00Z